Advaxis Inc has research in works for Prostate Cancer

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, last week announced two research projects involving the company's Lm Technology(TM) immunotherapy candidate ADXS-PSA, which is being developed for Prostate Cancer, have been selected as 2015 Movember Foundation-PCF Challenge Awards, sponsored by the Movember Foundation and the Prostate Cancer Foundation (PCF). Grants amounting to $1 million each have been awarded to two ADXS-PSA teams conducting innovative large-scale research projects concerning metastatic, treatment-resistant prostate cancer, an advanced form of the disease with often-lethal outcomes.